Primary Care’s Role in Skin Cancer Detection

Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

GLP-1RAs for Weight Management: Weighing Benefits vs Side Effects
September 03, 2025

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

FDA Approves Automated Insulin Delivery System for Adults With Type 2 Diabetes
September 03, 2025

FDA clears MiniMed 780G for integration with Abbott’s Instinct sensor and approves its use in insulin-requiring T2D, expanding automated insulin delivery options.

Data Shows Initial RSV Vaccine Uptake is Low Among Older Adults: Daily Dose
September 03, 2025

Your daily dose of the clinical news you may have missed.

Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 02, 2025

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians
September 02, 2025

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD
September 02, 2025

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis: Daily Dose
September 02, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Subcutaneous Leqembi Autoinjector for Maintenance Therapy in Early Alzheimer Disease
September 01, 2025

The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.

More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose
September 01, 2025

Your daily dose of the clinical news you may have missed.

Spotting the Subtle Signs of Depression: How Familiarity Helps Family Physicians Excel, With Teresa Lovins, MD
August 29, 2025

Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.